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Abstract
Background: the prevalence of crohn’s disease (cd)
is increased in patients with cystic fibrosis (cf). anti-
saccharomyces  cerevisiae  antibodies  (asca)  have
been suggested as a screening tool to detect cd in cf.
Recently, several new anti-glycan antibodies have been
reported in cd.
Materials and methods: the sera of 119 cf patients of
various  age  groups  were  prospectively  screened  for
asca type IgG (gasca), anti-laminaribioside carbo-
hydrate IgG antibodies (aLca), anti-chitobioside car-
bohydrate  Iga  antibodies  (acca),  and  anti-manno-
bioside  carbohydrate  IgG  antibodies  (aMca).  the
frequency  of  these  anti-glycan  antibodies  was  then
compared  in  patients  with  cd,  ulcerative  colitis,
rheumatoid arthritis and healthy volunteers. 
Results:  a  significant  number  of  cf  patients  were
positive  for  gasca  (51.3%  [41.6-60.6])  and  up  to
three other anti-glycan antibodies concurrently. serum
levels of anti-glycan antibodies in cf and cd were
not  related  to  parameters  of  inflammation.  despite
the well-documented difference in clinical course be-
tween male and female cf patients no gender differ-
ence of anti-glycan antibodies was found. In contrast,
there  was  a  significant  positive  correlation  between
anti-glycan markers and age in cf patients. 
Conclusions: our  findings  demonstrate  for  the  first
time the increased frequency of a panel of anti-glycan
antibodies in cf and provide a link between the pres-
ence of these serological biomarkers and patient’s age.
anti-glycan antibody profiling may therefore become a
valuable tool in the care of patients with cf.
Key words: cystic fibrosis, crohn’s disease, anti-glycan
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IntRodUctIon
cystic fibrosis (cf) is the most common autosomal
recessive inherited disease of caucasians with an inci-
dence of 1:2000 to 1:3000 [1]. the primary cellular
defect, the reduced expression of the cystic fibrosis
transmembrane conductance regulator (cftR), lead-
ing to diminished chloride secretion, is present in all
epithelial cells of endodermal and mesodermal origin
including  the  intestine  [2].  typical  gastrointestinal
complications of cf may manifest as meconium ileus
at  birth  or  distal  intestinal  obstruction  syndrome
(dIos) primarily occurring in adolescents and adults
[3, 4]. other gastrointestinal impairment may involve
constipation, intussusception, and rectal prolapse [3,
4]. However, many patients with cf have abdominal
symptoms which cannot be categorized into the above
mentioned conditions.
crohn’s  disease  (cd)  is  a  chronic  inflammatory
bowel disease (Ibd) in which non-pathogenic, com-
mensal  intestinal  bacteria  are  thought  to  trigger  a
chronic dysregulated immune response against mucos-
al barrier function (for review see [5]). In a prospective
multicentre study involving more than 11000 cf pa-
tients the prevalence of cd was reported to be 1:453,
a rate which is 17 times that of the control group [6].
due to a lack of a specific test for cd and overlap-
ping clinical features of both disorders the identifica-
tion of cd in cf patients is hampered.
In recent years much effort has been made to devel-
op  biomarkers  for  diagnosis,  stratification,  and  pre-
dicting of various diseases including cd. the major
serologic  markers  for  cd  are  anti-saccharomyces
cerevisiae antibodies (asca), which have been identi-
fied in up to 60% of adults and children with cd [7,
8]. asca belong to the group of anti-glycan antibod-
ies. Glycan is a generic term describing molecules with
glycosidic bonds, including mono-, oligo-, and poly-
saccarides as well as carbohydrates. they are predomi-
nant cell surface components of various types of cells
including erythrocytes, immune cells, and microorgan-
isms leading to a variety of anti-glycan antibodies of
all classes (for review see [9]). besides asca, three
novel  anti-glycan  antibodies  were  recently  identified
and associated with cd: anti-laminaribioside carbohy-
drate IgG antibodies (aLca), anti-chitobioside carbo-
hydrate Iga antibodies (acca), and anti-mannobio-
side carbohydrate IgG antibodies (aMca). Recent re-
sults have demonstrated that such serological markers
provide a panel that complement asca for disease di-
agnosis with a prevalence of 19 to 40% in cd patients
[10-12].
the potential use of asca as a tool in screening
patients with cf for cd was suggested previously by
demonstrating a higher frequency of asca seroposi-
tivity particularly in children with cf as compared to
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2) Hirche##_Umbruchvorlage  04.08.11  15:52  Seite 385the general population [13]. In this study, we aimed at
expanding the knowledge of the prevalence of anti-
glycan antibodies in both, children and adults with cf.
sUbJEcts and MEtHods
stUdy PoPULatIon
cf patients attending frankfurt university cf centre
between May 2007 and october 2008 were prospec-
tively enrolled in the study. diagnosis of cf was con-
firmed  by  a  sweet  test  (pilocarpin  iontophoresis)
and/or genetic testing in each case. Patient characteris-
tics (age, gender) and routine laboratory parameters,
including markers of inflammation (leukocyte count,
c-reactive protein [cRP]), were recorded. Individuals
who presented with symptoms of acute exacerbation
and/or  inflammation  were  excluded  from  the  study.
as a control, patients with cd, ulcerative colitis (Uc),
rheumatoid arthritis (Ra), and healthy volunteers were
also tested for seropositivity of anti-glycan antibodies.
Informed  consent  was  given  by  all  patients  and  the
study was performed in accordance with the principles
of the 1983 declaration of Helsinki.
MEasUREMEnt of antI-GLycan antIbodIEs
a  panel  of  anti-glycan  antibodies  (acc,  aLca,
aMca,  gasca)  was  determined  by  indirect  solid
phase  enzyme-linked  immunosorbent  assays  (IbdX,
Glycominds,  Lod,  Israel)  following  modification  of
previously  described  protocols  [14].  briefly,  blood
samples (10 ml, containing heparin) from patients and
controls were collected by venipuncture as prescribed
by local regulatory requirements. samples were sepa-
rated immediately from red blood cells and stored at -
80ﾰc until assayed. serum samples (10 ﾵl) were mixed
with sample diluent (1:100). next, 50 ﾵl of diluted
samples and pre-diluted controls/calibrator were incu-
bated for 30 minutes with mannobioside immobilized
in  microtiter  wells.  after  thorough  washing,  plates
were incubated for 30 minutes with enzyme labelled
(HRP) anti-human IgG. next, unbound serum conju-
gate was removed by washing and chromogenic sub-
strate (tMb) added for 15 minutes (aLca, gasca)
or  30  minutes  (aMca,  acca).  subsequently,  reac-
tions were terminated by addition of HRP stop solu-
tion and absorbance’s of calibrator, samples and con-
trols were evaluated spectrophotometrically (od 450
nm). the results correlate with the quantity of anti-
body  present  in  the  patient  sample  in  a  non-linear
fashion, a cut off threshold of 50 U/ml for each anti-
glycan antibody was established empirically.
statItIcaL MEtHods
Logarithmic  transformation  was  used  for  sufficient
normal distribution of clinical and biochemical vari-
ables which were expressed as mean ﾱ sEM or as me-
dian with quartiles (Q25% and Q75%), when appro-
priate. the correlation of anti-glycan antibodies in pa-
tients with cd was done by spearman’s rank correla-
tion  coefficient.  diagnostic  parameters  sensitivity
(sE), specificity (sP), positive predictive value (PPv),
negative  predictive  value  (nPv),  and  accuracy  were
calculated for prediction of cd by anti-glycan anti-
bodies using endoscopy and histological examination
as gold standard. In a multiple logistic regression mod-
el with stepwise forward selection of factors associat-
ed with cd, age, gender, leucocyte count, cRP, and
anti-glycan antibodies were included as potential pre-
dictors. comparison of groups was done by analyses
of  variance  (anova)  with  multiple  scheffe  test,  if
necessary. fishers exact test was used for categorical
variables.  assessment  of  statistical  significance  was
predefined with a two-sided level of 2α < 0.05. Re-
sulting p-values are presented descriptively with bon-
ferroni’s adjustment for multiple testing. all statistical
calculations were done by sas software, version 9.1,
sas Institute Inc., cary, Usa.
REsULts
In this study, 119 cf patients (70 children, 49 adults,
mean  age  ﾱ  sd:  23.8  ﾱ  11  years)  without  signs  of
acute exacerbation were included. for controls, 34 pa-
tients with cd (mean age ﾱ sd: 41.1 ﾱ 16 years), 11
patients with ulcerative colitis (mean age ﾱ sd: 38.1 ﾱ
17 years), 22 patients with rheumatoid arthritis (mean
age ﾱ sd: 57.9 ﾱ 13 years), as well as 16 healthy vol-
unteers (mean age ﾱ sd: 30.9 ﾱ 5 years) were included
(table 1). serology associated with cd (e.g., at least
one of the anti-glycan markers ≥ 50 U/ml) was fre-
quently  observed  in  patients  with  previously  deter-
mined cd, but rarely positive in the control groups. In
contrast, levels of anti-glycan antibodies, particularly
gasca, were markedly increased in cf patients com-
pared to the controls (p < 0.001) (fig. 1).
all four anti-glycan antibodies evaluated correlated
univariately with cd with rank correlation coefficients
of rs = 0.39 (p < 0.001), 0.36 (p < 0.001), 0.17 (p >
0.12), and 0.66 (p < 0.001) for aLca, aMca, acca,
and  gasca,  respectively.  However,  when  all  demo-
graphic and serological parameters were entered in a
multivariate logistic stepwise regression model, gas-
ca proved to be the only significant predictor associ-
ated with cd with a high odds ratio [95% cI] of 27
[8-93] (p < 0.001). gasca alone predicted cd with
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Fig.  1.  Increased  serum  levels  of  gasca  in  cf  patients.
shown are gasca serum levels (median, Q25%, Q75%) for
patients with cystic fibrosis (cf), crohn’s disease (cd), ulcer-
ative colitis (Uc), rheumatoid arthritis (Ra), as well as healthy
volunteers (Hc). dashed line indicates threshold for positive
anti-glycan titer (≥ 50 U/ml). asterisk indicates statistical sig-
nificance in the difference between cf and cd vs. Uc, Ra,
and Hc (p < 0.02, anova and scheffe test).
2) Hirche##_Umbruchvorlage  04.08.11  15:52  Seite 386good specificity (91,8%), but only moderate sensitivity
(76%) and accuracy (85,5%). combination of anti-gly-
can antibodies allowed to increase specificity to up to
100%, however, this resulted in poor results of other
operative test characteristics (table 2).
Previously,  presence  of  multiple  anti-glycan  anti-
bodies was found to be associated with a more com-
plicated and severe course in cd with a hazard ratio
of 2 to 4 [11]. while several patients with cd were
found  to  be  positive  for  up  to  all  four  anti-glycan
markers tested in this study, none of the controls were
positive for more than two. In contrast, a significant
number  of  cf  patients  were  positive  for  gasca
(51.3% (41.6-60.6)) and up to three other anti-glycan
antibodies concurrently, suggesting a close pathophys-
iological relation between cf and cd (fig. 2a-e).
serum levels of anti-glycan antibodies in cf and
cd disease were not related to parameters of inflam-
mation (data not shown). despite the well document-
ed difference in clinical course between male and fe-
male cf patients [14] we found no gender difference
of anti-glycan antibodies (male: 53,7% (41-66) vs. fe-
male: 48,0% (34-62)) (fig. 3). In contrast, there was a
moderate,  but  highly  significant  positive  correlation
between anti-glycan markers and age in cf patients.
this  phenomenon  was  particularly  prominent  for
gasca with spearmann’s correlation coefficient rs =
0.39  (p  <  0.001),  but  also  remained  present  when
combinations of multiple anti-glycan antibodies were
analysed (figs. 4 and 5).
dIscUssIon
besides the established role of asca in cd, systemat-
ic screening for other anti-glycan antibodies using gly-
can array has lead to the discovery of novel biomark-
ers that may be associated with Ibd. these include
gasca, acca, aLca, and aMca. there is mount-
ing evidence suggesting not only a diagnosing and dif-
ferentiating  capability  of  these  biomarkers  in  Ibd.
two  recent  studies  demonstrated  that  seropositivity
for the anti-glycan antibodies is associated with early
disease  onset,  complicated  disease  behaviour,  and
Ibd-related surgery [11, 15]. It appears that a combi-
nation of these biomarkers is superior to their single
use.  finally,  like  asca  acca,  aLca,  and  aMca
have been found to be linked to genetic susceptibility.
several studies clearly demonstrated an association be-
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Table 1. comparison of demographic and serological parameters used in this study.
Parameter CF (n=119) CD (n=34) UC (n=11) RA (n=22) HC (n=16) p < 0.05
Gender (m/f) 67/52 14/20 3/8 5/17 10/6 n.s.
Age 23.0 36.5 30.0 57.5 29.0 Ra vs. all
(years) [16 , 33]* [29 , 58] [25 , 61] [49 , 64] [28 , 34]
WBC 8.9 8.5 8.5 8.0 n.d. n.s.
(/nl) [7 , 11] [5 , 10] [6 , 11] [6 , 11]
CRP 0.3 0.4 0.3 0.3 n.d. n.s.
(mg/dl) [0.1 , 1.0] [0.1 , 1.2] [0.05 , 1,0] [0.1 , 3.9]
ALCA 18.8 30.8 16.3 14.3 23.3 cd vs. Ra
(U/ml) [12 , 32] [21 , 50] [12 , 29] [9 , 20] [19 , 31]
ACCA 22.2 35.4 30.0 24.1 35.6 n.s.
(U/ml) [17 , 39] [22 , 47] [16 , 40] [17 , 31] [27 , 42]
AMCA 29.9 32.8 23.1 23.8 30.6 n.s.
(U/ml) [23 , 46] [25 , 55] [16 , 26] [20 , 30] [20 , 40]
gASCA 55.6 88.9 20.5 20.0 23.0 cd vs.
(U/ml) [27 , 124] [51 , 143] [15 , 40] [14 , 27] [10 , 38] cU,Ra,Hc
continuous variables: median [Q25%, Q75%], wbc = white blood cell count; cRP = c-reactive protein; cf = cystic fibrosis;
cd = crohn’s disease; Uc = ulcerative colitis; Ra = rheumatoid arthritis; Hc = healthy volunteers. differences between
groups were compared by anova with scheffe-test or fisher’s exact test(*) with bonferroni.
Table 2. Performance characteristics of anti-glycan antibodies for detection of patients with crohn’s disease.
SE SP PPV NPV ACC
gASCA only 76.5 91.8 86.7 84.9 85.5
gASCA+1Ab 41.2 95.9 87.5 70.1 73.5
gASCA+2Ab 17.6 100.0 100.0 63.6 66.3
gASCA+3Ab 2.9 100.0 100.0 59.8 60.2
sE = sensitivity; sP = specificity; PPv = positive predictive value; nPv = negative predictive value; acc = accuracy; ab =
anti-glycan antibodies (acca, aLca, aMca). sera positive antibody titers were defined as ≥ 50 U/ml.
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tations  of  innate  immune  response  genes  such  as
nod2/caRd15  or  the  toll  like  receptors  (tLR)  2
and 4 [15, 16].
asca have previously also been described in cf. In
a  prospective  evaluation  among  young  cf  patients
aged 2 to 21 seropositivity for asca was found in 17
out of 82 patients (20.7%). Eight patients exhibited
antibodies  of  the  Iga  class,  six  had  IgG  antibodies
and three children had both. Interestingly, a statistical
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Fig. 2. Multiple anti-glycan antibodies detectable in cf pa-
tients. a-e, comparison of anti-glycan antibodies (% of sera
positive results ﾱ cI 95%) for patients with cystic fibrosis
(cf, a), crohn’s disease (cd, b), ulcerative colitis (Uc, c),
rheumatoid  arthritis  (Ra,  d),  as  well  as  healthy  volunteers
(Hc, e). Positive anti-glycan titer were defined as ≥ 50 U/ml.
X-axis indicates patients positive for gasca alone, or posi-
tive for gasca+ ≥ 1ab or gasca+ ≥ 2ab at the time, re-
spectively. Patients positive for gasca and ≥ 2 anti-glycan
markers were only found in cf and cd, but not in any of the
other groups.
Fig. 3.  serum levels of gasca are not dependent on gender in
cf patients. comparison of gasca (% of sera positive re-
sults with cI 95%) between male and female patients with
cystic fibrosis (cf) or crohn’s disease (cd). Positive anti-gly-
can titer were defined as ≥ 50U/ml.
Fig. 4. Increased levels of anti-glycan antibodies in adults pa-
tients with cf. comparison of anti-glycan antibodies (% of
sera positive results with cI95%) between children and adult
patients  with  cystic  fibrosis  (cf).  Positive  anti  glycan  titer
were defined as ≥ 50 U/ml. X-axis indicates patients positive
for gasca only (gasca pos), or gasca and additional anti-
glycan antibodies at the time (+ ≥ 1ab; ≥ 2ab, ≥ 3ab). as-
terisks indicate statistical significance for difference between
cf children and adults (p < 0.002, fisher’s exact test after
bonferroni’s adjustment).
Fig. 5. serum levels of gasca are increasing with age in cf
patients. scatter-plot of gasca according to age of cf pa-
tients. bold line represents line of regression (log gasca =
1.406 + 0.136 x age). dashed line indicates threshold for pos-
itive anti-glycan titer ≥ 50U/ml). correlation between gas-
ca and age was statistically significant (spearman’s rank cor-
relation  rs = 0.39, p < 0.001).
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could be observed, whereas no such relationship was
present  for  asca  Iga.  clinical  features  associated
with the presence of asca were not noticed in this
pediatric cf population [13]. screening sera for sever-
al antibodies in 144 adult patients with cf by Lachenal
et  al.  revealed  43.7%  to  be  positive  for  asca  Iga.
the presence of this biomarker correlated with both,
male  sex  and  hypergammaglobulinaemia.  further-
more, chronic respiratory failure, requested lung trans-
plantation, and fatal outcome were more frequent in
cf patients with asca Iga or autoantibodies against
bactericidal/permeability  increasing  protein  (bPI-
anca) [17]. 
our data adds further knowledge to the prevalence
of anti-glycan antibodies in patients with cf in differ-
ent age groups. for the first time the results of our
single-centre study clearly demonstrate a positive cor-
relation between asca and age. Moreover, similar to
cd  a  significant  proportion  of  adult  cf  patients
(16.9%) were positive for asca and one or even more
of three novel serologic anti-glycan antibodies acca,
aLca, and aMca. this phenomenon was found to
be in striking difference to other autoimmune diseases
such as ulcerative colitis and rheumatoid arthritis as
well as to healthy volunteers.
the clinical significance of this autoimmunity in cf
remains  obscure.  no  definite  clinical  symptoms  of
cd were detected in the seropositive patients of our
cf cohort. However, it has to be mentioned that en-
doscopic evaluation was not performed in any patient
to rule out cd, thus limiting the significance of our
study. In addition, there was no correlation between
the presence of the anti-glycan antibodies and either
gender, inflammation status (as determined by cRP),
and the clinical course of cf. 
Likewise, whether these antibodies target antigens
that have a pathogenic role in cf or whether these
markers  are  barely  indicators  of  increased  intestinal
permeability remains to be answered. the higher fre-
quency of anti-glycan antibodies in adult patients as
compared to pediatric cf patients suggests that the
generation of these serologic markers may be rather
promoted by longstanding or repeated inflammation
and nonspecific immune activation. In contrast, sever-
al related studies in cd suggest that the main mecha-
nism for the antibody production might be the loss of
the immune tolerance rather than an increase in in-
testinal permeability [18, 19]. a lack of correlation be-
tween serologic cd phenotypes and intestinal perme-
ability was reported by independent groups, indicating
that these markers are not an epiphenomenon related
to disease activity [19, 20, 21]. Moreover, an associa-
tion  between  cd  and  a  high  serologic  response  to
yeast and mannose as well as a specific lymphocyte re-
activity towards mannose compared with the food al-
lergen ovalbumin in asca-positive cd patients has
been demonstrated [22, 23]. these data imply that the
anti-microorganism response in cd is not merely due
to a generalized immunologic hyperreactivity toward
intestinal contents as would be expected if intestinal
permeability  were  the  main  mechanism.  finally,  the
detection of asca in cd patients before clinical di-
agnosis and the occurrence of antibodies in unaffect-
ed first-degree relatives of patients with cd also argue
against a leaky bowel theory [21, 24, 25].
to what extent these findings in cd can readily be
assigned to cf and whether the common response to
anti-glycan  antibodies  represents  a  pathogenetic  link
for the increased susceptibility of cf patients to cd is
unknown to date. In principle, two theories for the in-
creased anti-glycan antibody formation related to the
assumed vulnerability of the intestine in cf to devel-
op cd have to be considered. firstly, increased per-
meability [26] and impaired protein digestions due to a
lack of proteases [27] can lead to a high antigen load
to  the  intestinal  mucosa  in  cf.  secondly,  qualitative
and quantitative abnormalities in mucus secretion may
affect  the  access  and  recognition  of  antigens  that
cross the mucosal barrier [28]. In that way, clarke et al.
demonstrated in a murine cf model, that Paneth gran-
ules undergo limited dissolution and accumulate with-
in the crypts [29]. among the many antimicrobial ef-
fector molecules of Paneth cells defensins have been
demonstrated to play a pivotal role in innate immune
defence. as anti-glycan antibody formation has been
linked to nod2 mutations in cd which in turn may
lead to Paneth cell dysfunction and decreased defensin
production [30], it is intriguing to assume that anti-
body  formation  in  cf  might  be  the  result  of  de-
creased  antimicrobial  activity  due  to  decreased  de-
fensin secretion. However, this hypothesis has to be
scrutinized in further studies.
In conclusion, our study demonstrated for the first
time the increased frequency of a panel of anti-glycan
antibodies in cf and provided a link between the pres-
ence of these serological biomarkers and patient’s age.
our findings indicate that acca, aLca, aMca, and
gasca may be a valuable tool in the care of patients
with cf. However, the importance and clinical signifi-
cance has yet to be determined.
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